Teva Pharmaceutical Industries Limited Announces Launch of Generic ACTOplus met® in the United States

Published: Aug 20, 2012

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the launch of an authorized generic of ACTOplus met® (pioglitazone/metformin tablets)15 mg/500 mg, 15 mg/850 mg. ACTOplus met® is marketed by Takeda Pharmaceuticals U.S.A., Inc. and used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes. ACTOplus met® had annual sales of approximately $413 million in the United States, based on IMS sales data as of June 30, 2012.

Back to news